Article
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
Antiviral therapy - 1 Jan 2012
Liu Chen-Hua, Liang Cheng-Chao, Liu Chun-Jen, Tseng Tai-Chung, Lin Chih-Lin, Yang Sheng-Shun, Su Tung-Hung, Lin Jou-Wei, Chen Jun-Herng, Chen Pei-Jer, Chen Ding-Shinn, Kao Jia-Horng
Abstract excerpt
BACKGROUND: Pegylated interferon and ribavirin for 72 weeks improve sustained virological response (SVR) in HCV genotype 1 (HCV-1) slow viral responders. Whether interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and on-treatment viral responses can identify non-rapid virologi...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.